AB Science 過去の業績

過去基準チェック /06

AB Scienceは15.5%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで14%毎年増加している。売上は減少しており、年平均12.7%の割合である。

主要情報

15.5%

収益成長率

21.7%

EPS成長率

Pharmaceuticals 業界の成長	16.3%
収益成長率	-12.7%
株主資本利益率	n/a
ネット・マージン	-558.5%
前回の決算情報	30 Jun 2024

Recent updates

If You Had Bought AB Science (EPA:AB) Stock A Year Ago, You Could Pocket A 90% Gain Today

Feb 14

What Kind Of Shareholders Hold The Majority In AB Science S.A.'s (EPA:AB) Shares?

Dec 22

Our Take On AB Science's (EPA:AB) CEO Salary

Nov 17

収支内訳

AB Science の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ENXTPA:AB 収益、費用、利益 ( )EUR Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	1	-6	3	6
31 Mar 24	1	-9	3	8
31 Dec 23	1	-12	4	10
30 Sep 23	1	-14	3	11
30 Jun 23	1	-17	3	12
31 Mar 23	1	-15	3	13
31 Dec 22	1	-14	4	13
30 Sep 22	1	-15	4	14
30 Jun 22	1	-17	4	14
31 Mar 22	2	-16	4	13
31 Dec 21	2	-14	4	11
30 Sep 21	2	-13	4	12
30 Jun 21	2	-11	3	12
31 Mar 21	2	-13	3	12
31 Dec 20	2	-15	3	13
30 Sep 20	2	-16	3	12
30 Jun 20	2	-18	3	12
31 Mar 20	2	-20	3	14
31 Dec 19	2	-22	3	16
30 Sep 19	2	-25	3	19
30 Jun 19	2	-28	3	23
31 Mar 19	2	-27	3	25
31 Dec 18	2	-26	3	27
30 Sep 18	2	-25	3	27
30 Jun 18	2	-25	3	27
31 Mar 18	2	-26	3	27
31 Dec 17	2	-27	3	27
30 Sep 17	2	-27	3	26
30 Jun 17	2	-26	3	26
31 Mar 17	2	-27	3	27
31 Dec 16	2	-28	3	28
30 Sep 16	2	-28	4	27
30 Jun 16	2	-28	4	27
31 Mar 16	2	-28	4	25
31 Dec 15	2	-27	4	24
30 Sep 15	2	-24	4	21
30 Jun 15	2	-22	4	19
31 Mar 15	2	-19	4	16
31 Dec 14	2	-16	4	13
30 Sep 14	2	-16	4	13
30 Jun 14	2	-15	3	13
31 Mar 14	2	-15	3	12

質の高い収益: ABは現在利益が出ていません。

利益率の向上: ABは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ABは利益を出していないが、過去 5 年間で年間15.5%の割合で損失を削減してきた。

成長の加速: ABの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ABは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -19.9% ) と比較することは困難です。

株主資本利益率

高いROE: ABの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2025/01/08 22:36
終値	2025/01/08 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AB Science S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。6

アナリスト	機関
Mark van der Geest	ABN AMRO Bank N.V.
Michael Ryskin	BofA Global Research
Swayampakula Ramakanth	H.C. Wainwright & Co.

AB Science 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

Full year 2023 earnings released

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

Recent updates

AB Science Provides an Update on Its Ab8939 Program in Acute Myeloid Leukemia

New minor risk - Share price stability

AB Science Receives Notice of Allowance for European Patent Covering Masitinib Until 2040 in the Treatment of Sickle Cell Disease

First half 2024 earnings released: €0.09 loss per share (vs €0.22 loss in 1H 2023)

AB Science Announces Positive Results of Its Phase 2 Study Evaluating Masitinib in Covid-19

Insufficient new directors

New minor risk - Market cap size

AB Science S.A., Annual General Meeting, Jun 26, 2024

Full year 2023 earnings released

New minor risk - Financial data availability

AB Science Announces Eligibility granted by Health Canada for Reconsideration Request for Masitinib in ALS

Price target decreased by 27% to €6.90

AB Science S.A. to Report First Half, 2024 Results on Sep 30, 2024

AB Science Receives Notice of Allowance for European Patent Covering masitinib Until 2036 in the Treatment of mastocytosis

First half 2023 earnings released: €0.22 loss per share (vs €0.15 loss in 1H 2022)

New minor risk - Financial data availability

New minor risk - Financial data availability

New minor risk - Shareholder dilution

AB Science S.A. Receives Notice of Allowance for European Patent Covering Masitinib in the Treatment of Metastatic Castrate Refractory Prostate Cancer (mCRPC)

Full year 2022 earnings released: €0.29 loss per share (vs €0.30 loss in FY 2021)

AB Science S.A. to Report Fiscal Year 2022 Results on Apr 28, 2023

AB Science S.A. Receives Approval from the U.S. Food and Drug Administration (FDA) to Initiate the Confirmatory Phase 3 Study with Masitinib in the Treatment of Progressive Multiple Sclerosis

AB Science S.A. announced that it expects to receive €15 million in funding from European Investment Bank, Investment Arm

AB Science SA Receives Notice of Deficiency from Health Canada for Masitinib in Treatment of Amyotrophic Lateral Sclerosis

AB Science SA Receives U.S. Food and Drug Administration Authorization to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer’s Disease

AB Science Sa Receives First Agencies Authorizations to Initiate Confirmatory Phase 3 Clinical Study with Masitinib in the Treatment of Alzheimer's Disease

First half 2022 earnings released: EPS: €0 (vs €0.099 loss in 1H 2021)

AB Science SA Announces Positive Recommendation of Data and Safety Monitoring Board to Continue Phase 2 Study Evaluating Antiviral Activity of Masitinib in Covid-19

AB Science Announces That It Has Filed an Application for Conditional Marketing Authorization to EMA for Masitinib in the Treatment of ALS

AB Science SA Announces Publication of Results from its Positive Study of Masitinib in Severe Asthma Uncontrolled by Oral Corticosteroids in the Peer-Reviewed Journal of Asthma and Allergy

AB Science Announces Changes in the Board of Directors

AB Science S.A. Announces Publication of Results from Its Positive Pivotal Phase 3 Trial of Masitinib in Progressive Forms of Multiple Sclerosis in the Peer-Reviewed Journal Neurology® Neuroimmunology & Neuroinflammation

AB Science SA Announces Health Canada Has Granted Authorization to File New Drug Submission for Masitinib in the Treatment of ALS Under the Notice of Compliance with Conditions (NOC/c) Policy

AB Science SA Grants Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the Swedish Medical Products Agency

AB Science SA Receives Authorization to Initiate Phase II Study in Patients with Severe Mast Cell Activation Syndrome by the French Health Authority (ANSM)

AB Science Announces That It Has Been Granted Authorization to Initiate Confirmatory Phase III Trial of Masitinib in Progressive Forms of Multiple Sclerosis by the French Health Authority (ANSM)

AB Science S.A. Announces Dosing of First Patient in Phase 2 Trial of Masitinib’s Antiviral Activity Against the SARS-CoV-2 (Covid-19) Virus

AB Science Receives FDA Authorization to Initiate Phase 1/Ii Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia

First half 2021 earnings released: €0.099 loss per share (vs €0.23 loss in 1H 2020)

AB Science SA Receives Regulatory Authorization to Commence A Second Phase 2 Covid-19 Study

AB Science S.A. Receives Health Canada Approval Letter to Commence Phase I/II Trial of Ab8939 in the Treatment of Acute Myeloid Leukemia (AML)

AB Science S.A. Receives Authorization to Resume Patient Enrollment in the Phase 2 Masitinib Study of Covid-19

AB Science S.A. Receives New Authorizations to Resume Patient Enrollment in Its Phase 3 Studies of Masitinib

AB Science Announces Results from Masitinib Study Ab12003 in Prostate Cancer Have Been Presented At the 2021 American Urological Association

AB Science SA Announces That It Has Received Second Authorization to Resume Patient Enrollment, in the Phase 3 Study of Masitinib in Mastocytosis

AB Science Announces Receives the First Authorization to Resume Patient Enrollment in the Confirmatory Phase 3 Study of Masitinib (AB19001) in ALS

Price target increased to €23.11

AB Science Announces the Validation of Its Risk Management Plan by the French National Agency (ANSM) in Order to Restart Patient Enrollment in France

AB Science SA Announces Results from Masitinib Study AB12005 in Pancreatic Cancer Have Been Presented At the 2021 Asco Annual Meeting

AB Science SA Announces Update of Masitinib

AB Science SA Communicates Results from Phase 3 Study Evaluating Masitinib in Prostate Cancer

AB Science Sa Announces Results from Masitinib Study AB12005 in Pancreatic Cancer, Have Been Selected for Presentation at the Upcoming Asco Annual Meeting

Full year 2020 earnings released

AB Science Sa Announces Identification of Two Tissue Biomarkers That Could Potentially Serve as Predictive Biomarkers of Response for Masitinib Treatment

If You Had Bought AB Science (EPA:AB) Stock A Year Ago, You Could Pocket A 90% Gain Today

AB Science Announces a New Independent Publication Confirms That Masitinib Has Anti-Vital Activity Against the SARS-CoV-2 Virus in Vitro and Is A Promising Candidate for Treating COVID-19

AB Science S.A. has completed a Follow-on Equity Offering in the amount of €10.50001 million.

What Kind Of Shareholders Hold The Majority In AB Science S.A.'s (EPA:AB) Shares?

AB Science Issues A Corrective Press Release Regarding Adverse Events Information from Study AB09004 Reported on December 16, 2020

AB Science Announces That Phase 2B/3 Study Evaluating Oral in Alzheimer’S Disease Met Its Primary Endpoint

New 90-day high: €14.34

AB Science S.A. Announces That Confirmatory Phase 3 Study AB12005 with Masitinib in First Line Pancreatic Cancer with Pain Was Successful

Our Take On AB Science's (EPA:AB) CEO Salary

AB Science S.A. Announces Results from masitinib Study AB07015 in Severe Asthma Have Been Selected for Presentation At an ATS Symposium Held on October 16, 2020

First half earnings released

AB Science SA Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Large Multiple Sclerosis Research Conference

New 90-day high - €12.58

New 90-day high - €9.50

収支内訳

過去基準チェック /06